RaQualia Pharma Inc. announced non-consolidated earnings results for the six months ended June 30, 2016. For the period, the company reported net sales of JPY 617 million, operating loss of JPY 173 million, ordinary loss of JPY 235 million and net loss of JPY 241 million or net loss per share of JPY 12.88 against net sales of JPY 45 million, operating loss of JPY 948 million, ordinary loss of JPY 897 million, and net loss of JPY 922 million or net loss per share of JPY 62.07 a year ago. Loss before tax was JPY 237.985 million against JPY 917.210 million a year ago. Net cash used in operating activities was JPY 671.812 million against JPY 1,249.162 million a year ago. Purchase of property, plant and equipment was JPY 27.167 million against JPY 40.029 million a year ago. Purchase of intangible assets was JPY 0.988 million against JPY 0.192 million a year ago.

For the year ending December 31, 2016, the company expects net sales of JPY 950 million, operating loss of JPY 819 million, ordinary loss of JPY 823 million and net loss of JPY 832 million or net loss per share of JPY 44.37.